Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00644137 · ClinicalTrials.gov registry record · Early Phase 1
GABA (Gamma Amino Butyric Acid) Medication for Tobacco
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT00644137 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 24 participants.
The verdict
NCT00644137, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this study is to examine the effects of a GABA (gamma amino butyric acid)-enhancing medication, pregabalin (300 mg/day), on smoking behavior, tobacco withdrawal and cigarette craving in smokers. We hypothesize that in smokers, pregabalin at 300 mg/day, will be more effective than placebo in decreasing smoking behavior and attenuating tobacco withdrawal and cigarette craving.
Interventions
- DRUG pregabalin
- OTHER cigarettes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00644137
The ClinicalTrials.gov registry entry for NCT00644137 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pregabalin is the first listed.
NCT00644137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00644137 about?
NCT00644137 is a clinical study titled "GABA (Gamma Amino Butyric Acid) Medication for Tobacco". The goal of this study is to examine the effects of a GABA (gamma amino butyric acid)-enhancing medication, pregabalin (300 mg/day), on smoking behavior, tobacco withdrawal and cigarette craving in smokers. We hypothesize that in smokers, pregabalin at 300 mg/day, will be more effective than placebo...
What is the current status of trial NCT00644137?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2007-08. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00644137?
The interventions under investigation include: pregabalin (DRUG), cigarettes (OTHER).
Who is sponsoring clinical trial NCT00644137?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.